Table 1.
Baseline characteristics of patients with and without SGLT2is
| Characteristics | Total | SGLT2is | No SGLT2is | P-value |
|---|---|---|---|---|
| Patients, n (%) | 4446 (100) | 1598 (35.9) | 2848 (64.1) | |
| Age (years), mean ± SD | 60.6 ± 13.5 | 56.0 ± 12.0 | 63.1 ± 13.5 | <.0001 |
| Gender (male), n (%) | 2328 (52.4) | 884 (55.3) | 1445 (50.7) | .056 |
| Race, n (%) | <.0001 | |||
| Chinese | 2565 (57.7) | 884 (55.3) | 1681 (59.0) | |
| Malay | 865 (19.5) | 341 (21.3) | 523 (18.4) | |
| Indian | 638 (14.4) | 259 (16.2) | 379 (13.3) | |
| Other | 378 (8.5) | 113 (7.1) | 265 (9.3) | |
| ACEi, n (%) | 1066 (24) | 516 (32.3) | 1082 (38.0) | <.0001 |
| ARB, n (%) | 1788 (40.2) | 814 (50.9) | 784 (27.5) | <.0001 |
| Diuretics, n (%) | 1143 (25.7) | 235 (14.7) | 908 (31.9) | <.0001 |
| eGFR at baseline (mL/min/1.73 m2), mean ± SD | 69.9 ± 31.7 | 83.9 ± 26.4 | 62.0 ± 31.8 | <.0001 |
| uACR at baseline (mg/mmol), median (IQR) | 6.8 (1.5–43.5) | 7.2 (1.4–51.5) | 5.9 (1.5–37.2) | .281 |
| HbA1c at baseline (%), mean ± SD | 8.3 ± 1.7 | 8.8 ± 1.5 | 8.1 ± 1.7 | <.0001 |
| CKD stages, n (%) | <.0001 | |||
| eGFR ≥45 mL/min/1.73 m2 | 3220 (724) | 1458 (91.2) | 1762 (61.9) | |
| eGFR 15–44 mL/min/1.73 m2 | 1226 (27.6) | 140 (8.8) | 1086 (38.1) |
ACEi, angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker.